News and Trends 18 Oct 2017 German Researchers Set the Immune System Free to Fight Against Cancer …T cells at bay. But, the mechanisms used by the body to control the immune system have been manipulated by cancers that can now hide, safe from the cells that… October 18, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2017 GSK wants in on Adaptimmune’s Adaptable T cell Cancer Treatment …big player that is not far behind. The ability of Adaptimmune to tweak their T cells to particular cancer proteins will help them to find niches within the field. They… September 8, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 22 Dec 2022 10 biotech companies to watch in 2023 …disease (aGVHD), a condition that can arise when a patient is given a bone marrow transplant and transplanted immune cells attack the host body. To treat inflammation, Mesoblast sources a… December 22, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 28 Apr 2017 This Dutch Biotech Could Boost Gene Editing of Primary Cells …to a transient cell manipulation since the protein-coding genes are not integrated into the genome, thus also lowering the risk of off-target effects. Images via shutterstock.com / TasfotoNL and hubrecht.eu… April 28, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 30 Mar 2017 New Clues on How the Immune System Weakens with Age …the immune system weakens with age. Their findings, which were published in the high-impact journal Science, show that immune cells in older tissues lack coordination and exhibit much more variability… March 30, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
In Depth 3 Dec 2025 Boehringer Ingelheim’s pipeline activity: A busy year of dealmaking for the German pharma in 2025 …the German giant, as last year it said it was turning its attention to a deep late-stage pipeline that could bring 25 new treatments to market over the next decade. … December 3, 2025 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 4 Feb 2025 Akribion Therapeutics emerges from stealth with programmable cell depletion RNA technology …directly targeting tumor-associated antigens to activate the immune system, like CAR-T therapy, nor does it rely on ADCs that bind to membrane proteins on cancer cells. “G-dase E specifically targets… February 4, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Apr 2025 21 UK biotech companies you should know about …therapeutic proteins that do not exist in nature. This approach allows for the development of proteins that can be tailored to specific functions, and it could also expand drug targets,… April 24, 2025 - 27 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2020 SynOx Joins Wave of Biotechs Attacking Solid Tumor ‘Comfort Zone’ …the two broad camps of traditional cancer treatments: those that kill cancer cells directly, and those that boost the immune system’s natural ability to destroy cancer cells. Instead, it is… November 23, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2020 French Manufacturing Plant Launches to Make Cell Therapy Cheap and Scalable …this new facility, Treefrog Therapeutics aims to produce cell therapies using ten times less space and investment than the current manufacturing standard. The biotech will employ the facility to fuel… June 9, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2023 New promising targeted drug for a rare leukemia …now shows that venetoclax does not appear to be effective against erythroid and megakaryoblastic leukemias, two rare subtypes of the disease that are difficult to treat. In these leukemia types,… February 23, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 29 Oct 2024 GPCR therapies: Eight promising biotechs hacking the cell signaling pathway …TT-702 works by making cancer more visible to the immune system so that the cells can be destroyed. It is currently in phase 1 trials to treat difficult-to-treat cancers such… October 29, 2024 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email